血友病的基因疗法:临床实验室的机遇和挑战
Armando Tripodi1,2, Isabella Garagiola1,2, Niccolò Bitto1
1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy.
Clinical chemistry
|August 12, 2025
概括
使用腺相关病毒载体的基因治疗有效地通过向肝脏输送凝血因子来治疗血友病A和B. 在这种先进的治疗中,患者选择和测试方法对于成功的结果至关重要.
科学领域:
- 血液学 血液学 血液学
- 基因治疗 基因治疗
- 凝血障碍 凝血障碍 凝血障碍
背景情况:
- 血友病A和B是X关联疾病,导致VIII (FVIII) 或IX (FIX) 因素低或功能障碍.
- 目前的治疗方法包括替代疗法和FVIII模拟剂,如埃米齐祖马布.
- 利用腺相关病毒载体 (AAVV) 的基因疗法 (GT) 已成为一种新的治疗选择.
研究的目的:
- 审查血友病A和B的基因疗法的当前状态.
- 讨论基于AAVV的基因疗法的关键考虑因素,包括载体,输送,位器官和治疗因素的测量.
- 评估基因治疗在临床实践中的有效性和挑战.
主要方法:
- 编码为FVIII或FIX的基因材料被纳入了AAVV.
- AAVV被输注给患者,向肝细胞进行FVIII/FIX生产.
- 患者选择标准强调没有肝病的最佳结果.
主要成果:
- 临床试验表明,基因疗法维持了血FVIII/FIX水平,并减少了出血发作.
- 转基因因子水平可以使用一阶段凝血试验 (OSA) 或染色体试验 (CA) 来测量.
- 一般来说,OSA报告的转基因因子水平较高 (大约为1. 2x) 与CA相比.
结论:
- 使用AAVV的基因疗法是对血友病A和B的可行和有效治疗方法.
- 仔细选择患者,特别是肝脏健康,对于成功的基因疗法至关重要.
- 虽然存在专家偏好 (OSA用于FIX,CA用于FVIII),但需要进一步的证据来确定与临床结果相关的最佳试验.
相关概念视频
00:59Gene Therapy
25.9K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.9K
01:29Microorganisms in Medicine and Therapeutics
330
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
330